Ophidion, Inc. is a private biotechnology company with a platform technology called the Ophidion CNS Carrier Technology (OCCT), which uses a Trojan horse strategy to exploit an endogenous receptor-mediated transport system to deliver various therapeutic cargos, including biologics, into the brain for the treatment of various CNS disorders and brain malignancies. We are currently focused on developing a pipeline to deliver gene silencing therapies to treat neurodegenerative diseases, including Huntington’s disease, as well as diseases of Cognitive Impairment (e.g. Alzheimer’s disease, Parkinson’s disease). The platform technology is amenable to delivering multiple classes of drugs (including small molecules and macromolecules (gene-silencing therapeutics, siRNAs, ASOs, cDNAs, antibodies, peptides, and other macromolecules) across the blood-brain barrier into the brain following intravenous administration. Ophidion owns multiple issued patents in the US, Europe and Japan.